9550
document
Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation . A multicenter , placebo-controlled , randomized , double-blind trial compared the preventive effect of aprindine and digoxin on the recurrence of atrial fibrillation ( AF ) with placebo , and also compare the effectiveness of these 2 drugs in the prevention of AF . Patients with symptomatic paroxysmal or persistent AF who had converted to sinus rhythm ( SR ) were randomly assigned aprindine ( 40 mg/day ) , digoxin ( 0.25 mg/day ) or placebo and followed up on an outpatient basis every 2 weeks for 6 months . Of the 141 patients from 36 participating centers , 47 were given aprindine , 47 digoxin , and 47 were on placebo . After the 6-month follow-up , the Kaplan-Meier estimates of the percentage of patients remaining free of recurrent symptomatic AF on aprindine , digoxin and placebo were 33.3 % , 29.2 % and 21.5 % , respectively . In patients remaining in SR for 15 days after from the start of follow-up , freedom from recurrence was significantly more prevalent in the aprindine group than in the placebo group ( p=0.0414 ) , but there was no significant difference between the digoxin and placebo groups . The rate of adverse events was similar in the 3 groups . In conclusion , neither aprindine nor digoxin had a significant effect on preventing relapse of symptomatic AF ; however , recurrence of AF occurred later with aprindine than with placebo or digoxin .
9551
Intervention_Control
placebo-controlled
9552
Intervention_Pharmacological
aprindine
9553
Intervention_Pharmacological
digoxin
9554
Intervention_Control
placebo-controlled
9555
Intervention_Pharmacological
aprindine
9556
Intervention_Pharmacological
digoxin
9557
Intervention_Control
placebo
9558
Intervention_Pharmacological
aprindine
9559
Intervention_Pharmacological
digoxin
9560
Intervention_Pharmacological
placebo
9561
Intervention_Pharmacological
aprindine
9562
Intervention_Pharmacological
digoxin
9563
Intervention_Control
placebo
9564
Intervention_Pharmacological
aprindine
9565
Intervention_Pharmacological
digoxin
9566
Intervention_Control
placebo
9567
Intervention_Control
placebo
9568
Intervention_Pharmacological
digoxin
9569
Intervention_Pharmacological
aprindine
9570
Intervention_Control
placebo
9571
Intervention_Pharmacological
digoxin
9572
Outcome_Physical
prevention of symptomatic atrial fibrillation .
9573
Outcome_Other
preventive effect
9574
Outcome_Physical
recurrence of atrial fibrillation ( AF )
9575
Outcome_Other
effectiveness
9576
Outcome_Physical
prevention of AF .
9577
Outcome_Physical
Kaplan-Meier
9578
Outcome_Physical
recurrent symptomatic AF
9579
Outcome_Other
freedom from recurrence
9580
Outcome_Physical
significant difference
9581
Outcome_Adverse-effects
rate of adverse events
9582
Outcome_Other
preventing relapse of symptomatic AF
9583
Outcome_Other
recurrence of AF
9584
Participant_Condition
symptomatic atrial fibrillation
9585
Participant_Condition
atrial fibrillation ( AF
9586
Participant_Condition
symptomatic paroxysmal
9587
Participant_Condition
persistent AF
9588
Participant_Condition
sinus rhythm ( SR
9589
Participant_Sample-size
141
9590
Participant_Sample-size
36
9591
Participant_Sample-size
47 were given aprindine
9592
Participant_Sample-size
47 digoxin
9593
Participant_Sample-size
47 were on placebo